Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical evaluation of peptichemio.

W E Grose, M A Burgess, G P Bodey

    Cancer Treatment Reports
    |March 1, 1979
    PubMed
    Summary

    Peptichemio, a peptide complex of m-L-phenylalanine mustard, showed a 7% partial remission rate in solid tumors. Key side effects included myelotoxicity and phlebitis, with an optimal dose of 45 mg/m2/day for 3 days.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1992
    Same author

    Infectious complications of indwelling vascular catheters.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
    Same author

    Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of common community respiratory viruses.

    Seminars in respiratory infections·1992
    Same author

    Lack of activity of amphotericin B in systemic murine fusarial infection.

    The Journal of infectious diseases·1992
    Same author

    Evaluation of strategies for central venous catheter replacement.

    Critical care medicine·1992
    Same author

    Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Peptichemio is a peptide complex derived from m-L-phenylalanine mustard.
    • Clinical efficacy and toxicity of novel chemotherapeutic agents are crucial in cancer treatment.

    Purpose of the Study:

    • To evaluate the clinical efficacy and toxicity of Peptichemio in patients with solid tumors.
    • To determine the optimal dose schedule and identify potential toxicities associated with Peptichemio administration.

    Main Methods:

    • A clinical trial involving 116 patients with solid tumors.
    • Peptichemio administered intravenously (iv) at doses ranging from 20-75 mg/m2/day for 3 days, with courses repeated every 3-4 weeks.

    Main Results:

    • 104 patients were evaluable for toxicity and response.
    • The optimal dose schedule identified was 45 mg/m2/day for 3 days.
    • A 7% partial remission rate was observed across various solid tumors, including melanoma, lymphoma, and carcinomas of the gastrointestinal, genitourinary, breast, and head and neck.
    • Major side effects included cumulative myelotoxicity, phlebitis, and mild nausea/vomiting, with no other major organ toxicity noted.
    • Responses lasted between 4-36 weeks.

    Conclusions:

    • Peptichemio demonstrates modest efficacy in solid tumors, with a 7% partial remission rate.
    • The recommended optimal dose is 45 mg/m2/day for 3 days.
    • Cumulative myelotoxicity and phlebitis are the primary dose-limiting toxicities, necessitating careful patient monitoring.

    Related Experiment Videos